Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of YFQLXB-UC01 injection in acute-on-chronic liver failure
CTR20251631Phase 2Active
- Sponsor
- Qilu Cell Therapy
- Start
- May 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord mesenchymal stem cells (Shandong Province Qilu Stem Cells Engineering) in acute-on-chronic liver failure (ACLF), sponsored by Qilu Cell Therapy. Started May 2025; status: active.
02
Drugs
umbilical cord mesenchymal stem cells (Shandong Province Qilu Stem Cells Engineering)
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on CTR20251631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251631.